U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Business Wire•03/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.